HYPOPHARYNX SQUAMOUS CELL CARCINOMA
Clinical trials for HYPOPHARYNX SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HYPOPHARYNX SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HYPOPHARYNX SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New study aims to spare patients unnecessary radiation to the neck
Disease control Recruiting nowThis phase 3 trial tests whether using a sentinel lymph node biopsy can help doctors decide which side of the neck needs radiation, instead of treating both sides in all patients. About 242 adults with certain head and neck cancers will be randomly assigned to standard bilateral …
Matched conditions: HYPOPHARYNX SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated May 26, 2026 07:24 UTC
-
New drug cocktail aims to shrink Hard-to-Treat head and neck tumors
Disease control Recruiting nowThis study tests whether combining two drugs, sacituzumab govitecan and cetuximab, can shrink tumors in people with advanced head and neck cancer that has gotten worse after first-line therapy. About 40 adults with certain types of head and neck cancer will receive the drug combi…
Matched conditions: HYPOPHARYNX SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
New weekly drug combo offers hope for head and neck cancer patients unable to take standard chemo
Disease control Recruiting nowThis study tests a weekly combination of chemotherapy (carboplatin and paclitaxel) plus immunotherapy (pembrolizumab) in 32 people with metastatic head and neck cancer who cannot take the standard drug 5-fluorouracil. The goal is to see if this regimen shrinks tumors better than …
Matched conditions: HYPOPHARYNX SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated May 19, 2026 12:00 UTC